Scarica l'app Stockscreener
3.21
2.72%
0.085
Dopo l'orario di chiusura:
3.44
0.23
+7.17%
Precedente Chiudi:
$3.125
Aprire:
$3.18
Volume 24 ore:
8,216
Relative Volume:
0.51
Capitalizzazione di mercato:
$114.35M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+10.85%
1M Prestazione:
+5.25%
6M Prestazione:
+34.31%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.12
$3.2799
Intervallo di 1 settimana:
$2.845
$3.2799
Portata 52W:
$2.20
$4.08
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Nome
Eupraxia Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta EPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.21 | 114.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Borsa (EPRX) Ultime notizie
Knee Osteoarthritis Pipeline 2024: Key Companies, MOA, ROA, - openPR
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.5% – Time to Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 3.5%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% – Here’s What Happened - Defense World
Eupraxia Pharmaceuticals Inc - Stockhouse Publishing
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 1.7% – Still a Buy? - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Increase in Short Interest - Defense World
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Growth in Short Interest - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 1% – Should You Sell? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1%Here's Why - MarketBeat
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 3.3% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) & Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Financial Analysis - Defense World
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases - The Eastern Progress Online
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Re - GuruFocus.com
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brok - GuruFocus.com
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Eupraxia Pharmaceuticals Strengthens Senior Management Team - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
Eupraxia Pharma Shares Jump Following Data From Eosinophilic Esophagitis Trial - MarketWatch
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - The Malaysian Reserve
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Re - GuruFocus.com
Eupraxia Pharmaceuticals Inc (EPRX-T) QuotePress Release - The Globe and Mail
Eupraxia Pharmaceuticals to Present at American College of Rheum - GuruFocus.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw - Defense World
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Eupraxia Pharmaceuticals files report with SEC - Investing.com
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com Australia
RODMAN&RENSHAW Upgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to "Strong-Buy" - MarketBeat
Rodman & Renshaw rates Eupraxia stock Buy on 'groundbreaking delivery tech' - Investing.com Canada
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - Canada NewsWire
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - BioSpace
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Rodman & Renshaw - MarketBeat
Eupraxia Pharmaceuticals reports regulatory update - Investing.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 – Company AnnouncementFT.com - Financial Times
Newswire - KelownaNow
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Malaysian Reserve
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Finansavisen - Finansavisen
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4%What's Next? - MarketBeat
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - Yahoo Finance
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement - Troutman Pepper
Eupraxia Pharmaceuticals Shares Rise After Completing Private Placement - MarketWatch
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million - Quantisnow
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - Quantisnow
Eupraxia Pharmaceuticals Inc Azioni (EPRX) Dati Finanziari
Non sono disponibili dati finanziari per Eupraxia Pharmaceuticals Inc (EPRX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):